Clinical trial · Observational
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
Prospective Assessment of Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We are interested in studying whether and how medical problems other than primary cancer before hematopoietic cell transplantation would impact the profiles of quality of life and toxicities post-transplantation for patients with blood cancers. We want to see if by assessing comorbidities (such as diabetes) early on, we can identify those patients who will have more toxicities or limitations in their quality of life after transplant. The generated information could set the stage for future intervention studies aiming to improve quality of life for patients with blood cancers after transplantation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | PROBABILISTIC | 0.70 |
| Other Diagnoses, Comorbidities, and Complications | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- The MD Anderson Symptom Inventory
- timeFrame
- Change from Baseline in Symptoms at 3,6,12,and 24 months
- description
- A 19-item instrument, it assesses physical symptoms and their interference with life.
- measure
- The Functional Assessment of Cancer Therapy Bone Marrow Transplant Scale
- timeFrame
- Change from Baseline in Symptoms at 3,6,12,and 24 months
- description
- A 49-item questionnaire measuring quality of life in bone marrow transplant patients, it measures physical, functional, social/family and emotional well-being in addition to bone marrow transplant-specific concerns.
- measure
- The EQ-5D
- timeFrame
- Change from Baseline in Symptoms at 3,6,12,and 24 months
- description
- This measure is used to measure utilities that can be used to calculate a quality adjusted survival score.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Allogeneic HCT candidates who are \>18 years of age * Able to speak and read English * Able to provide informed consent * Access to a telephone for study-related communications * Diagnosed with a hematological malignant disease * Willing to complete survey packets at 5 time-points, spanning two years Exclusion Criteria: * HCT candidates who are 18 years or younger at the time of study enrollment * HCT candidates who cannot read, write, or speak English * Patients with diagnoses of non-malignant diseases, or solid tumors are primary disease
References
Publications (0)
Data not yet available